You are here

  • Home
  • Archive
  • Volume 10, Issue 6
  • Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

 

Online download statistics by month:

Online download statistics by month: June 2022 to April 2026

AbstractFullPdf
Jun 2022571594222
Jul 2022372381142
Aug 202215761593296
Sep 2022605633141
Oct 202241641880
Nov 202233534184
Dec 202221021172
Jan 202320320573
Feb 202320120596
Mar 202314014673
Apr 202312112148
May 202314114350
Jun 2023939437
Jul 2023888950
Aug 202312012134
Sep 2023777935
Oct 20239910144
Nov 202311412137
Dec 2023143143140
Jan 2024100103311
Feb 202412312660
Mar 202410410595
Apr 202411612047
May 2024899035
Jun 202411911851
Jul 202410310447
Aug 2024737134
Sep 202410210333
Oct 202410210245
Nov 2024798045
Dec 202437137945
Jan 202511011061
Feb 202514714738
Mar 2025919136
Apr 202510810831
May 202511211241
Jun 2025757541
Jul 2025110
Apr 2026310
Total775378852850